PDSB Key Statistics, Chart & Performance
The current stock price of PDSB is 0.7177 USD. In the past month the price decreased by -28.02%. In the past year, price decreased by -51.03%.
PDSB Technical Analysis
PDSB Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to PDSB. Both the profitability and financial health of PDSB have multiple concerns.
PDSB Financial Highlights
Over the last trailing twelve months PDSB reported a non-GAAP Earnings per Share(EPS) of -0.82. The EPS increased by 29.91% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -100.52% | ||
| ROE | -369.02% | ||
| Debt/Equity | 1.26 |
PDSB Forecast & Estimates
9 analysts have analysed PDSB and the average price target is 7.65 USD. This implies a price increase of 965.9% is expected in the next year compared to the current price of 0.7177.
PDSB Ownership
PDSB Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.23 | 394.886B | ||
| AMGN | AMGEN INC | 16.68 | 206.949B | ||
| GILD | GILEAD SCIENCES INC | 17.02 | 189.204B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.1 | 121.258B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.75 | 82.557B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.37 | 43.353B | ||
| INSM | INSMED INC | N/A | 31.961B | ||
| BIIB | BIOGEN INC | 12.79 | 29.513B | ||
| NTRA | NATERA INC | N/A | 28.022B | ||
| INCY | INCYTE CORP | 13.58 | 21.279B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About PDSB
Company Profile
PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. The company is headquartered in Princeton, New Jersey and currently employs 24 full-time employees. The company went IPO on 2015-10-01. The firm is developing a pipeline of targeted cancer immunotherapies based on its Versamune T cell-activator and Versamune in combination with its interleukin 12 (IL-12) fused antibody drug conjugate (ADC), PDS01ADC, a tumor targeting immunocytokine. PDS0101 is its lead Versamune based immunotherapy. PDS0101 combines Versamune with a mixture of short proteins (peptides) derived from the cancer-causing HPV16 viral protein. Versamune is a proprietary lipid nanoparticle and T cell activating platform. PDS0301 is an investigational tumor-targeting antibody conjugate of Interleukin 12 (IL-12) that enhances the proliferation, potency, infiltration, and longevity of T cells in the tumor microenvironment. Its Versamune immunotherapies and Versamune in combination with PDS01ADC, are utilized for treatments in oncology, and Infectimune is utilized for preventive vaccines against infectious agents.
Company Info
PDS BIOTECHNOLOGY CORP
303A College Road East
Princeton NEW JERSEY 07932 US
CEO: Frank Bedu-Addo
Employees: 24
Phone: 18002083343
PDS BIOTECHNOLOGY CORP / PDSB FAQ
Can you describe the business of PDS BIOTECHNOLOGY CORP?
PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. The company is headquartered in Princeton, New Jersey and currently employs 24 full-time employees. The company went IPO on 2015-10-01. The firm is developing a pipeline of targeted cancer immunotherapies based on its Versamune T cell-activator and Versamune in combination with its interleukin 12 (IL-12) fused antibody drug conjugate (ADC), PDS01ADC, a tumor targeting immunocytokine. PDS0101 is its lead Versamune based immunotherapy. PDS0101 combines Versamune with a mixture of short proteins (peptides) derived from the cancer-causing HPV16 viral protein. Versamune is a proprietary lipid nanoparticle and T cell activating platform. PDS0301 is an investigational tumor-targeting antibody conjugate of Interleukin 12 (IL-12) that enhances the proliferation, potency, infiltration, and longevity of T cells in the tumor microenvironment. Its Versamune immunotherapies and Versamune in combination with PDS01ADC, are utilized for treatments in oncology, and Infectimune is utilized for preventive vaccines against infectious agents.
Can you provide the latest stock price for PDS BIOTECHNOLOGY CORP?
The current stock price of PDSB is 0.7177 USD. The price increased by 0.38% in the last trading session.
Does PDS BIOTECHNOLOGY CORP pay dividends?
PDSB does not pay a dividend.
How is the ChartMill rating for PDS BIOTECHNOLOGY CORP?
PDSB has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the analyst forecast for PDSB stock?
9 analysts have analysed PDSB and the average price target is 7.65 USD. This implies a price increase of 965.9% is expected in the next year compared to the current price of 0.7177.
What is the market capitalization of PDSB stock?
PDS BIOTECHNOLOGY CORP (PDSB) has a market capitalization of 37.59M USD. This makes PDSB a Nano Cap stock.